However, despite our promising mechanistic studies identifying MAPK8IP1 as an inflammasome regulator, the therapeutic potential of using MAPK8IP1 to ameliorate T2D seems to be impeded by its role in β-cell function and insulin secretion. Here, INS is linked to type 2 diabetes mellitus.